News: Research and development

View:
 

Found press releases

 

Chairman increases holdings in Diamyd

5/17/2013 11:23 AM EST  -   Diamyd Medical AB
The Chairman of Diamyd Medical, Anders Essen-Möller, has today bought 1,429,656 shares in Diamyd Medical and his holdings in Diamyd Medical amounts after the transaction to 479,292 series A-shares and 1,617,397 series B-shares, representing approximately 21% of the capital and about 45% of the votes.

Report from the extra general meeting

5/17/2013 3:52 AM EST  -   ChronTech Pharma AB
At the extra general meeting (EGM) in ChronTech Pharma AB (below ”the Company”) on the 16th of May it was resolved to accept the board’s proposal for restructuring of the company and transfer of the Company’s projects regarding development of DNA-vaccines against hepatitis B and hepatitis C in accordance with the Term Sheet, which was put forward at the EGM and which earlier has been attached to the notice for the...

New Diamyd Medical listed on NASDAQ OMX First North on May 20, 2013

5/15/2013 11:35 AM EST  -   Diamyd Medical AB
Diabetes has developed into a major global problem. The disorder is affecting younger and younger people and complications related to diabetes are currently among the most common causes of death in many countries. In conjunction with the spin-out of the new Diamyd Medical from the Parent Company in April 2013, a dedicated diabetes company was formed. The company will now be listed on NASDAQ OMX First North and the...

Karolinska Development´s Annual General Meeting 2013

5/15/2013 2:00 AM EST  -   Karolinska Development AB (publ)
STOCKHOLM - May 15, 2013. At the Annual General Meeting of Karolinska Development AB held May 14, 2013, the following resolutions were passed, in accordance with the presented proposals:
Profit and loss statement: It was resolved to adopt the profit and loss statement and the balance sheet and the consolidated profit and loss statement and the consolidated balance sheet.

Appropriation of the result: It was...

Finnish researchers to provide solutions for energy-efficient repairs in residen...

5/15/2013 1:55 AM EST  -   VTT Info
There are many old and decrepit residential buildings in Moscow in need of refurbishment. VTT Technical Research Centre of Finland has developed three repair concepts for improving the energy efficiency of both buildings and entire residential districts while also reducing their environmental impact. Calculations show that it would be possible to reduce heating demand in buildings by up to 70%. Even minor repairs...

Diamyd broadens the diabetes portfolio

5/14/2013 9:15 AM EST  -   Diamyd Medical AB
Diamyd Medical has concluded a new exclusive licensing agreement with the University of California in Los Angeles (UCLA) relating to a patent portfolio for the therapeutic use of GABA (gamma-aminobutyric acid) in connection with type 1 diabetes and other inflammatory disorders such as type 2 diabetes, metabolic syndrome and rheumatoid arthritis. The agreement covers, for example, one patent application for a...

U.S. FDA grants priority review to Simeprevir for combination treatment of genot...

5/13/2013 8:00 AM EST  -   Medivir
Stockholm, Sweden — Medivir AB (OMX: MVIR) today announces that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the New Drug Application (NDA) by Janssen for simeprevir (TMC435), an investigational NS3/4A protease inhibitor administered as a 150 mg capsule once daily with pegylated interferon and ribavirin for the treatment of genotype 1 chronic hepatitis C in adult patients with...

Karolinska Development AB (publ) - Interim report January - March 2013

5/10/2013 2:00 AM EST  -   Karolinska Development AB (publ)
STOCKHOLM – May 10, 2013. Karolinska Development AB (publ) announces publication of its Interim report January-March, 2013. A conference call will be held today at 14.00 CET. Participant access numbers: SE: +46 (0)8 506 307 79, UK: +44 (0) 1452 555 131, or US: +1 866 682 8490. The full report and a link to the webcast are available on the company's website.
Torbjörn Bjerke, CEO, comments: “During the first...

The European Spallation Source is Inviting Potential Partners to Contribute to t...

5/8/2013 10:31 AM EST  -   European Spallation Source AB
The European Spallation Source has released a “Call for Expressions of Interest” to research institutes and other organisations to participate in the project with in-kind contributions. The call broadly encourages potential partners to contribute in many ways, usually in the form of technical components, or work.
With this call, ESS starts the process of identifying and agreeing with those partners who will...

Medivir Q1 audiocast 2013

5/7/2013 4:44 PM EST  -   Medivir
Medivir presents the Q1 report in this audiocast.
Watch the audiocast below:http://livecast.wehay.com/playontv/130506/medivir/